Thiambutosine | CAS#500-89-0

Thiambutosine
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 329997

CAS#: 500-89-0

Description: Thiambutosine was a candidate for treatment of lepromatous leprosy.

Chemical Structure

Thiambutosine

CAS# 500-89-0

Instruction

Theoretical Analysis

MedKoo Cat#: 329997
Name: Thiambutosine
CAS#: 500-89-0
Chemical Formula: C19H25N3OS
Exact Mass: 343.17
Molecular Weight: 343.489
Elemental Analysis: C, 66.44; H, 7.34; N, 12.23; O, 4.66; S, 9.33

Price and Availability

Size	Price	Availability	Quantity
100mg	USD 650
200mg	USD 950
500mg	USD 1450
1g	USD 1950
2g	USD 2950
5g	USD 4950
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Thiambutosine; SC 682; SC682; SC-682; SU-1906; SU1906; SU 1906; Summit 1906; Ciba 1906;

IUPAC/Chemical Name: 1-(p-Butoxyphenyl)-3-(p-dimethylaminophenyl)-2-thiourea

InChi Key: JYCBKPOKWDDOOV-UHFFFAOYSA-N

InChi Code: InChI=1S/C19H25N3OS/c1-4-5-14-23-18-12-8-16(9-13-18)21-19(24)20-15-6-10-17(11-7-15)22(2)3/h6-13H,4-5,14H2,1-3H3,(H2,20,21,24)

SMILES Code: S=C(NC1=CC=C(N(C)C)C=C1)NC2=CC=C(OCCCC)C=C2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 343.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Smith TC, Richardus JH. Relapse rates in patients treated with dapsone monotherapy and combinations of dapsone and thiambutosine, thiacetazone, isoniazid and streptomycin in the pre-MDT era. Int J Lepr Other Mycobact Dis. 1994 Sep;62(3):353-8. PubMed PMID: 7525795.

2: Evans AT, Croft SL, Peters W, Neal RA. Antileishmanial effects of clofazimine and other antimycobacterial agents. Ann Trop Med Parasitol. 1989 Oct;83(5):447-54. PubMed PMID: 2619361.

3: Khan HM. Clinical therapeutic analysis of vitiligo phase--II. Bangladesh Med Res Counc Bull. 1984 Dec;10(2):71-5. PubMed PMID: 6543425.

4: Mikhailov P, Dimitrova I. [Leprosy in Bulgaria. Epidemiology, Clinical forms and treatment (author's transl)]. Z Hautkr. 1981 Oct 15;56(20):1364-70. German. PubMed PMID: 7197852.

5: Anand LC, Tiwari VD, Rathore BS, Singh O. Clinical trial with CIBA 1906 in lepromatous leprosy. Lepr India. 1981 Apr;53(2):278-84. PubMed PMID: 7019567.

6: Pattyn SR, Colston MJ. Cross-resistance amongst thiambutosine, thiacetazone, ethionamide and prothionamide with Mycobacterium leprae. Lepr Rev. 1978 Dec;49(4):324-6. PubMed PMID: 84317.

7: Colston MJ, Hilson GR, Ellard GA, Gammon PT. The activity of thiacetazone, thiambutosine, thiocarlide and sulphamethoxypyridazine against Mycobacterium leprae in mice. Lepr Rev. 1978 Jun;49(2):101-13. PubMed PMID: 78428.

8: Waters MF, Rees RJ, Pearson JM, Laing AB, Helmy HS, Gelber RH. Rifampicin for lepromatous leprosy: nine years' experience. Br Med J. 1978 Jan 21;1(6106):133-6. PubMed PMID: 339995; PubMed Central PMCID: PMC1602838.

9: Gangadharam PR, Candler ER. Activity of some antileprosy compounds against Mycobacterium intracellulare in vitro. Am Rev Respir Dis. 1977 Apr;115(4):705-8. PubMed PMID: 557943.

10: Waters MF, Pearson JM, Rees RJ. Drug resistant leprosy--a comparison between proven dapsone and proven thiambutosine resistance. Int J Lepr Other Mycobact Dis. 1976 Jan-Jun;44(1-2):152-3. PubMed PMID: 776850.

11: Colston MJ, Hilson GR. The activity of thiacetazone, thiambutosine and thiocarlide in the chemotherapy of experimental leprosy. Int J Lepr Other Mycobact Dis. 1976 Jan-Jun;44(1-2):123. PubMed PMID: 58847.

12: Levy L, Ullmann NM. Inhibition of multiplication of Mycobacterium leprae by several antithyroid drugs. Am Rev Respir Dis. 1975 May;111(5):651-5. PubMed PMID: 48349.

13: Devani MB, Shishoo CJ, Mody HJ. Spectrophotometric determination of thiambutosine. Analyst. 1975 Mar;100(1188):178-81. PubMed PMID: 1137192.

14: Verbov J. Use of CIBA 1906 (Thimbutosine BP) in vitiligo. Br J Dermatol. 1972 Jul;87(1):81-2. PubMed PMID: 5043208.

15: Convit J, Browne SG, Languillon J, Pettit JH, Ramanujam K, Sagher F, Sheskin J, Tarabini G, de Souza Lima L, Tolentino JG, Waters MF, Bechelli LM, Martínez Domínguez V. Therapy of leprosy. Bull World Health Organ. 1970;42(5):667-72. PubMed PMID: 5311056; PubMed Central PMCID: PMC2427498.

16: Garrod JM, Ellard GA. Appearance of resistance during prolonged treatment of leprosy with Thiambutosine. Lepr Rev. 1968 Jul;39(3):113-7. PubMed PMID: 5663677.

17: Draper P. Effects of a substituted diphenylthiourea (Ciba 1906) on Mycobacterium smegmatis NCTC 8159. Tubercle. 1967 Jun;48(2):151-9. PubMed PMID: 6058033.

18: Témime P, Privat Y, Benne M. [Tuberculoid development of a lepromatous form of Hansen's disease treated with a derivative of thiourea (Ciba 1906)]. Bull Soc Fr Dermatol Syphiligr. 1966 May-Jun;73(3):285-6. French. PubMed PMID: 5962550.

19: Schulz EJ, Egnal ML, Doevendans G. Treatment of leprosy with a combination of injectable thiambutosine (CIBA 1906), streptomycin and isoniazid. Lepr Rev. 1966 Jan;37(1):47-8. PubMed PMID: 5908575.

20: Ellard GA. A preliminary study of the absorption, metabolism and excretion of injectable thiambutosine. Lepr Rev. 1966 Jan;37(1):17-22. PubMed PMID: 5908570.

Your view history

Thiambutosine featured